Dar es Salaam. A new experimental malaria vaccine known as SUM-101 has produced encouraging findings in its first trial among Tanzanian adults previously exposed to malaria.
The study, led by researchers Aina-ekisha Kahatano and Maxmillian Mpina of the Ifakara Health Institute (IHI), shows the vaccine is safe, well-tolerated, and capable of triggering a strong immune response, marking a significant advance in global malaria research.
